Terms: = Head and neck cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
1657 results:
1. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
Ruan Y; Ma Y; Ma M; Liu C; Su D; Guan X; Yang R; Wang H; Li T; Zhou Y; Ma J; Zhang Y
J Transl Med; 2024 May; 22(1):471. PubMed ID: 38762454
[TBL] [Abstract] [Full Text] [Related]
2. Isobutyric acid enhances the anti-tumour effect of anti-pd-1 antibody.
Murayama M; Hosonuma M; Kuramasu A; Kobayashi S; Sasaki A; Baba Y; Narikawa Y; Toyoda H; Isobe J; Funayama E; Tajima K; Sasaki A; Maruyama Y; Yamazaki Y; Shida M; Hamada K; Hirasawa Y; Tsurui T; Ariizumi H; Ishiguro T; Suzuki R; Ohkuma R; Kubota Y; Horiike A; Sambe T; Tsuji M; Wada S; Kobayashi S; Shimane T; Tsunoda T; Kobayashi H; Kiuchi Y; Yoshimura K
Sci Rep; 2024 May; 14(1):11325. PubMed ID: 38760458
[TBL] [Abstract] [Full Text] [Related]
3. The efficacy and safety of adding pd-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis.
Jin YN; Qiang MY; Wang Y; Lin YJ; Jiang RW; Cao WW; Zhang WJ; Wang SY; Zhang HY; Yao JJ
Cancer Immunol Immunother; 2024 May; 73(7):125. PubMed ID: 38733402
[TBL] [Abstract] [Full Text] [Related]
4. A nomogram based on the SII3 and clinical indicators predicts survival in patients with nasopharyngeal carcinoma treated with pd-1 inhibitors.
Chen X; Liang W; Wu X; Wang Y; Hong Y; Xie M; Han R; Lin Z
Medicine (Baltimore); 2024 May; 103(19):e38017. PubMed ID: 38728499
[TBL] [Abstract] [Full Text] [Related]
5. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.
Yehan Z; Sheng Q; Hong Y; Jiayu L; Jun H; Juan J; Min S; Jiaxin Y; Shangzhi H; Yi W; Qifeng W; Xuefeng L; Wenwu H; Xueyan C; Yang L; Zongyao H
Front Immunol; 2024; 15():1312380. PubMed ID: 38726002
[TBL] [Abstract] [Full Text] [Related]
6. Breaking Ground in Recurrent or Metastatic head and neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
[TBL] [Abstract] [Full Text] [Related]
7. Enhanced CTLA-4 blockade anti-tumor immunity with APG-157 combination in a murine head and neck cancer.
Shin DS; Basak S; Veena MS; Comin-Anduix B; Bhattacharya A; Dong TS; Ko A; Han P; Jacobs J; Moatamed NA; Avila L; Pellegrini M; Wang M; Srivatsan ES
Cancer Med; 2024 May; 13(9):e7212. PubMed ID: 38686626
[TBL] [Abstract] [Full Text] [Related]
8. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
[TBL] [Abstract] [Full Text] [Related]
9. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
10. Spatiotemporal characteristics of tissue derived small extracellular vesicles is associated with tumor relapse and anti-pd-1 response.
Fu QY; Xiong XP; Xia HF; Liu XC; Yu ZL; Liu KW; Zeng J; Sun YF; Jia J; Chen G
Cancer Lett; 2024 Jun; 591():216897. PubMed ID: 38631664
[TBL] [Abstract] [Full Text] [Related]
11. Difference between Keratinized- and Non-Keratinized-Originating Epithelium in the Process of Immune Escape of Oral Squamous Cell Carcinoma.
Kitsukawa Y; Fukumoto C; Hyodo T; Komiyama Y; Shiraishi R; Koike A; Yagisawa S; Kunitomi Y; Hasegawa T; Kotani W; Ishida K; Wakui T; Kawamata H
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612630
[TBL] [Abstract] [Full Text] [Related]
12. [Phase Ⅱ clinical trial of pd-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma].
Wang HL; Yue K; Wu YS; Duan YS; Jing C; Wang XD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):335-342. PubMed ID: 38599641
[No Abstract] [Full Text] [Related]
13. Enhanced oral versus flank lymph node T cell response parallels anti-pd1 efficacy in head and neck cancer.
Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
[TBL] [Abstract] [Full Text] [Related]
14. pd-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.
Gao L; Tang L; Peng J; Hu Z; Yang J; Liu B
Front Immunol; 2024; 15():1353445. PubMed ID: 38576619
[TBL] [Abstract] [Full Text] [Related]
15. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
Ji G; Yang Q; Wang S; Yan X; Ou Q; Gong L; Zhao J; Zhou Y; Tian F; Lei J; Mu X; Wang J; Wang T; Wang X; Sun J; Zhang J; Jia C; Jiang T; Zhao MG; Lu Q
Genome Med; 2024 Apr; 16(1):49. PubMed ID: 38566201
[TBL] [Abstract] [Full Text] [Related]
16. Correlation Between ImageJ and Conventional Manual Scoring Methods for Programmed Death-Ligand 1 Immuno-Histochemically Stained Sections.
Al Taher RS; Abbas MA; Halahleh K; Sughayer MA
Technol Cancer Res Treat; 2024; 23():15330338241242635. PubMed ID: 38562094
[No Abstract] [Full Text] [Related]
17. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Dang S; Li X; Liu H; Zhang S; Li W
Cancer Med; 2024 Apr; 13(7):e7119. PubMed ID: 38553943
[TBL] [Abstract] [Full Text] [Related]
18. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-pd-1 therapy resistance.
Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
[TBL] [Abstract] [Full Text] [Related]
19. Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
Kim EY; Ruiz ES; DeSimone MS; Shalhout SZ; Hanna GJ; Miller DM; Schmults C; Rettig EM; Foreman RK; Sethi R; Thakuria M; Silk AW
JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):414-420. PubMed ID: 38546619
[TBL] [Abstract] [Full Text] [Related]
20. RNA splicing regulator EIF3D regulates the tumor microenvironment through immunogene-related alternative splicing in head and neck squamous cell carcinoma.
Lu D; Mihoayi M; Ablikim Y; Arikin A
Aging (Albany NY); 2024 Mar; 16(7):5929-5948. PubMed ID: 38535990
[TBL] [Abstract] [Full Text] [Related]
[Next]
